HWHG(SH:600079) Zhong Guo Jing Ji Wang·2026-02-25 02:35Core Viewpoint - ST Renfu (600079.SH) has announced a plan to issue A-shares to a specific entity, Zhaoshang Biotechnology, which is the controlling shareholder of the company, aiming to raise between RMB 300 million and RMB 350 million for various projects, including innovative drug research and development [1][2]. Group 1: Share Issuance Details - The share issuance will involve Zhaoshang Biotechnology, which currently controls 28.30% of the company, and the issuance will be conducted through cash subscription [1][2]. - The issuance price is set at RMB 14.95 per share, which is 80% of the average trading price over the previous 20 trading days [1]. - The total number of shares to be issued will be between 200,668,897 and 234,113,712, not exceeding 30% of the company's total share capital prior to the issuance [1]. Group 2: Fund Utilization - The raised funds will be allocated to several projects, including: - Innovative drug R&D project at Yichang Renfu with a total investment of RMB 104,202.45 million - Innovative drug R&D project at the headquarters with a total investment of RMB 63,850 million - Construction of a manufacturing base for sexual health and complex formulations with a total investment of RMB 79,000 million - Digital transformation project with a total investment of RMB 21,201 million - Supplementing working capital with a total investment of RMB 81,746.55 million - The total planned use of raised funds is RMB 350 million [2]. Group 3: Shareholding Structure Post-Issuance - After the issuance, Zhaoshang Biotechnology and its concerted parties will control approximately 37.29% of the company, maintaining its status as the controlling shareholder [2].